Journal of Extracellular VesiclesCancer BiologyPeer-reviewed journal article
Therapeutic poxviruses induce the secretion of immunostimulating and anti-tumoral extracellular vesicles
Lucas Walther, Vincent MittelheisseriD, Marie‐Christine Claudepierre, Louis BochleriD, Magali RompaisiD, Jules DeforgesiD, Nathalie SilvestreiD, Annabel LarnicoliD, Christine CarapitoiD, Éric QuéméneuriD, Jacky G. GoetziD, Karola RittneriD, Vincent HyenneiD
Abstract
Poxvirus-based vectors provide a versatile cancer immunotherapy platform, enabling the expression of immunostimulatory molecules and cancer-specific antigens. While infections with pathogenic viruses are well known to modulate extracellular vesicle (EV) biogenesis and function, the extent to which therapeutic poxviral vectors influence EV secretion by immune cells and thereby affect therapeutic efficacy remains underexplored. In this study, we showed that poxviruses, including the clinically relevant Modified Vaccinia Ankara (MVA), stimulate the secretion of small EVs (sEVs) containing viral proteins and immune-related signatures from peripheral blood mononuclear cells (PBMCs). Using an engineered MVA vector, we demonstrated the transfer of virus-encoded therapeutic payloads to sEVs, including the model ovalbumin (OVA)-derived peptide SIINFEKL presented by the class I major histocompatibility complex (MHC I) and the immune activators interleukin-12 (IL-12) and CD40 ligand (CD40L). Depending on the isolation method, these sEVs stimulated SIINFEKL-specific CD8 T cells with varying efficiencies in vitro. Remarkably, intravenous injection of these sEVs into E.G7-OVA lymphoma-bearing mice reduced tumor growth to an extent comparable to the virus itself. Taken together, our findings indicate that EVs released from immune cells infected with engineered therapeutic poxviruses exert potent antitumor activity. These vesicles represent actionable mediators whose secretion and functionalization can be harnessed to improve viral vector-based immunotherapies, as well as being considered as therapeutic vectors in their own. Graphical Abstract O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=95 SRC="FIGDIR/small/677320v1_ufig1.gif" ALT="Figure 1"> View larger version (20K): org.highwire.dtl.DTLVardef@1eae18borg.highwire.dtl.DTLVardef@17d6fb5org.highwire.dtl.DTLVardef@311577org.highwire.dtl.DTLVardef@7839c7_HPS_FORMAT_FIGEXP M_FIG C_FIG
- organism: mouse
- assay: bulk RNA-seq
- research focus: cancer & tumor microenvironment
- research focus: cell type annotation
- research focus: cell-cell communication
- research focus: drug response / drug discovery
- approach: experimental assay
- Citations
- 0
- FWCI
- 0.00
- Field percentile
- 1th percentile
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Long-term antitumor CD8+ T cell immunity induced by endogenously engineered extracellular vesicles
F. Ferrantelli, F. Manfredi, … M. Federico·bioRxiv·Feb 5, 2021
- Surface-engineered extracellular vesicles to modulate antigen-specific T cell expansion for cancer immunotherapy
X. Lyu, T. Yamano, … R. Hanayama·bioRxiv·Sep 25, 2023
- Engineered immunomodulatory extracellular vesicles derived from epithelial cells acquire capacity for positive and negative T cell co-stimulation in cancer and autoimmunity
F. Kugeratski, V. LeBleu, … R. Kalluri·bioRxiv·Nov 2, 2023
- Extracellular vesicles and co-isolated endogenous retroviruses differently affect dendritic cells
F. Cocozza, l. martin jaular, … C. Thery·bioRxiv·Jan 27, 2023
- Development of an engineered extracellular vesicles-based vaccine platform for combined delivery of mRNA and protein to induce functional immunity
Xin Luo, Kathleen M. McAndrews, … Raghu Kalluri·bioRxiv·Mar 14, 2024
- Complexes Formed by Mixing Tumor-derived Extracellular Vesicles with Polymeric Surfactants for Personalized Therapeutic Vaccine